Polypeptide Benefits: How Polypeptides Are Used in Health and Skincare

Key Takeaways

• Rapidly-growing pharmaceutical class: A 2023 review by Sharma and colleagues in Drug Discovery Today documented that peptide therapeutics represent one of the fastest-growing segments of pharmaceutical development, with peptides accounting for roughly 6% of all FDA-approved drugs and more than 100 peptide drugs approved to date.
• Broadest applications: FDA-approved polypeptide drugs span metabolic disease (insulin, GLP-1 agonists), oncology, cardiovascular disease, hormone deficiency, and HIV-related conditions.
• Skin evidence: Oral collagen peptides have the strongest consumer-level evidence base — a 2023 systematic review and meta-analysis covering 26 RCTs and 1,721 participants found significant improvements in skin elasticity and hydration.
• Topical evidence: Signal peptides used in skincare have in vitro and some human observational support; supporting trial evidence is less robust than for oral collagen.
• Evidence tiers matter: FDA-approved polypeptide medications have decades of Phase 3 trial data. Consumer supplements vary from well-supported (collagen peptides) to largely uncharacterized.

Polypeptides occupy an unusual position in science and commerce: the same structural category that includes insulin — one of the most important drugs in medical history — also encompasses a collagen cream on a pharmacy shelf. Understanding what polypeptides actually do requires sorting by evidence tier, not by marketing category.

This article covers the major domains of polypeptide benefit: pharmaceutical medicine, skin biology, nutritional applications, and drug delivery. For each, the evidence standard is stated explicitly.

What Polypeptides Are and Why Structure Matters

A polypeptide is a chain of amino acids connected by peptide bonds, typically containing 20 or more amino acids. The sequence of those amino acids — the primary structure — determines how the chain folds into a three-dimensional shape, and that shape determines what the polypeptide can do biologically. A 2023 review by Sharma and colleagues in Drug Discovery Today peptides in FDA-approved drug class — reporting that peptides account for roughly 6% of all FDA-approved drugs, with more than 100 peptide drugs approved to date under broad peptide-drug definitions, reflecting decades of work translating polypeptide biology into clinical medicine. A 2024 database analysis by Jain and colleagues (THPdb2) in Drug Discovery Today catalogued 85 FDA-approved therapeutic peptides and polypeptides under stricter inclusion criteria, spanning cancer, metabolic disease, hormone deficiency, and infectious disease — a measure of how broadly the category has proven clinically useful. The core reason polypeptides are so therapeutically versatile is receptor specificity: a particular polypeptide sequence binds a particular receptor, producing a targeted downstream effect. That same precision makes polypeptides valuable in skincare and nutrition, where receptor binding in skin and gut tissue produces measurable biological responses.

Discovery and historical context

The therapeutic use of polypeptides began with insulin in 1921, when Frederick Banting and Charles Best isolated the pancreatic hormone and demonstrated its ability to treat fatal diabetic ketoacidosis. Apostolopoulos and colleagues, in a 2021 review in Molecules, noted that peptide therapy has been evolving for over 100 years since insulin's first clinical use. The decades since have seen polypeptide biology expand from endocrine replacement therapy into oncology, metabolic medicine, antimicrobial applications, and cosmetic formulation.

Polypeptide Benefits in Therapeutic Medicine

The most well-characterized polypeptide benefits are those established through FDA-reviewed clinical trials. This category includes compounds with defined mechanisms, measured efficacy, and labeled safety profiles — a fundamentally different standard than consumer supplements.

Insulin: the quintessential therapeutic polypeptide

Insulin is a 51-amino acid polypeptide hormone that regulates blood glucose by facilitating cellular glucose uptake. It is produced by beta cells in the pancreatic islets as a precursor (proinsulin) and processed into its two-chain active form via post-translational cleavage. Rahman and colleagues, in a 2021 review in the International Journal of Molecular Sciences, insulin's role in health and disease, covering glucose regulation, anabolic signaling, and its central role in metabolic disease. Mayer, Zhang, and DiMarchi, writing in Biopolymers in 2007, detailed how insulin's two-chain architecture and disulfide bridge configuration enable the precise receptor-binding geometry required for glucose uptake signaling. Insulin's benefit as a therapeutic polypeptide derives from its precise three-dimensional structure, which enables it to bind the insulin receptor with the specificity required to trigger glucose disposal. Small-molecule insulin-receptor agonists remain an active research area but have not yet replaced polypeptide insulin in clinical practice.

Recombinant growth hormone: polypeptide hormone replacement

Growth hormone (GH) is a 191-amino acid polypeptide produced by somatotroph cells in the anterior pituitary. Aghili and colleagues, writing in Molecular Biology Reports in 2025, established GH signaling mechanisms and clinical implications across growth promotion, metabolic regulation, and tissue repair. Recombinant GH (somatotropin) is FDA-approved for specific diagnosed conditions — growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic kidney disease-associated growth failure, short stature homeobox-containing gene deficiency, and HIV-associated wasting — and is not approved for anti-aging, athletic performance, or general body composition uses. Reh and Geffner, in a 2010 review in Clinical Pharmacology: Advances and Applications, reviewed clinical evidence for recombinant somatotropin in GH deficiency and Turner syndrome, establishing its therapeutic benefit in precisely the population for which its endogenous biology is relevant. GH's clinical benefit derives from its 191-amino acid sequence producing the specific tertiary structure that engages the GH receptor — a structural point that illustrates why polypeptide therapeutics must be manufactured to exacting standards.

GLP-1 receptor agonists and tirzepatide: metabolic polypeptide medicine

GLP-1 receptor agonists represent the most commercially significant polypeptide drug class of the current era. Wang and colleagues, in a 2022 review in Signal Transduction and Targeted Therapy, examined therapeutic peptides including GPCR-targeting agents, with GLP-1 agonists as the leading clinical example. As of April 2026, semaglutide is FDA-approved under the brand name Ozempic for type 2 diabetes, and under Wegovy for chronic weight management and for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. Nauck and D'Alessio, writing in Cardiovascular Diabetology in 2022, reviewed tirzepatide as a dual GIP/GLP-1 receptor co-agonist, reporting greater HbA1c reduction and weight loss than single-target GLP-1 agonists in head-to-head trials. As of April 2026, tirzepatide is FDA-approved for type 2 diabetes (Mounjaro), chronic weight management in adults with obesity or overweight with weight-related comorbidities, and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound) — reflecting the compound's approved use across three distinct metabolic and cardiometabolic indications. A 2024 review by Al Musaimi in the Journal of Peptide Science documented FDA-approved peptide breakthroughs across cardiovascular disease, HIV, CNS disorders, and metabolic medicine, placing GLP-1 agonists in the broader context of polypeptide pharmaceutical progress.

Antimicrobial polypeptides: innate immunity and drug pipeline

Antimicrobial polypeptides (AMPs) are produced by virtually all living organisms as a first-line defense against pathogens. In human biology, defensins and cathelicidins are the major endogenous classes. Zasloff, writing in Nature in 2002, established antimicrobial peptides as fundamental components of innate immunity, documenting their mechanisms of action against bacteria, fungi, viruses, and parasites. Chen and Lu, in a 2020 review in Antibiotics, reviewed challenges in developing antimicrobial peptides for therapeutic applications, including stability, manufacturing, and resistance potential. The therapeutic antimicrobial peptide pipeline targets antimicrobial-resistance contexts in which conventional antibiotics have lost efficacy. As of April 2026, most next-generation AMP candidates remain in preclinical or early-clinical development rather than routine clinical use, though several long-established AMP-derived drugs (such as polymyxins and daptomycin) are FDA-approved for specific indications.

Polypeptide Benefits for Skin: What the Evidence Shows

Skin is a major site of polypeptide activity. Collagen is the most abundant protein in skin — itself a polypeptide structure — and the cells that produce it (fibroblasts) respond to polypeptide signals. Evidence for skin benefits divides clearly between oral collagen peptides (where controlled trial evidence is strongest) and topical signal peptides (where mechanistic evidence is solid but clinical trial data is more limited).

Oral collagen peptides: the RCT evidence base

Collagen peptides are low-molecular-weight polypeptide fragments produced by hydrolysis of collagen protein. Oral collagen peptides are regulated as dietary supplements under DSHEA; claims about skin appearance benefits are structure-function claims that have not been evaluated by FDA for drug-approval purposes. Pu and colleagues conducted a systematic review and meta-analysis published in Nutrients in 2023, covering 26 randomized controlled trials and 1,721 participants, which skin hydration and elasticity RCT findings associated with oral collagen peptide supplementation — the highest-quality evidence base for any consumer polypeptide supplement. Proksch and colleagues, in a double-blind RCT published in Skin Pharmacology and Physiology in 2014, demonstrated that oral collagen peptide supplementation improved skin elasticity and hydration in women aged 35 to 55 over eight weeks versus placebo. Kim and colleagues, in an RCT published in Nutrients in 2018, showed oral low-molecular-weight collagen peptide improved hydration, elasticity, and wrinkling over 12 weeks. Miyanaga and colleagues, in an RCT published in Skin Pharmacology and Physiology in 2021, reported that oral collagen peptides increase stratum corneum natural moisturizing factors, providing a mechanistic explanation for the hydration improvements observed across trials.

Topical signal peptides: mechanism and evidence

Signal peptides used in skincare formulations are typically synthetic short polypeptides designed to interact with skin cell receptors and influence extracellular matrix biology. Jeong and colleagues, in a 2019 review in the International Journal of Molecular Sciences, reviewed anti-wrinkle benefits of peptide complexes stimulating skin basement membrane protein expression, covering signal peptides, carrier peptides, and neurotransmitter-inhibitor peptides. He and colleagues, in a 2023 review in Frontiers in Pharmacology, examined the role of peptide-cell surface interactions in cosmetic peptide applications, including the mechanism by which palmitoyl-KTTKS (the active sequence in Matrixyl) signals collagen synthesis pathways in dermal fibroblasts. Choi and colleagues, in a 2014 study published in Biomolecules & Therapeutics, showed that collagen pentapeptides demonstrate dermal stability and skin permeation properties sufficient to support topical activity. As cosmetic ingredients, these peptides are regulated by the FDA under cosmetic labeling rules and are not approved to diagnose, treat, or prevent any medical condition.

Wound healing applications

Collagen-derived polypeptides have documented wound-healing properties at the cellular level. Mistry and colleagues, writing in Clinical and Experimental Dermatology in 2021, collagen peptide fibroblast migration markers, consistent with wound-closure activity at the cell-culture level (not human clinical trials). A 2024 review by Li and colleagues in the Journal of Agricultural and Food Chemistry examined the wound-healing potential of collagen peptides and their molecular mechanisms, covering fibroblast proliferation, angiogenesis promotion, and anti-inflammatory signaling. Maia Campos and colleagues, in a 2019 study in the Journal of Cosmetic Dermatology, reviewed both topical and oral peptide approaches for improving skin viscoelasticity and density, providing a comparison of the two routes that supports the conclusion that oral delivery achieves more systemic benefit while topical delivery targets the skin surface directly.

Polypeptides as Drug Delivery Vehicles

Beyond acting as drugs themselves, polypeptides are used as biocompatible scaffolds for delivering other therapeutics — a category distinct from polypeptide pharmacology but increasingly important in cancer medicine and targeted therapy.

Stimuli-responsive polypeptide nanoparticles

Synthetic polypeptides can be engineered to respond to specific environmental signals. Zhang and colleagues, in a 2021 review in Chemical Communications, catalogued stimuli-responsive polypeptide systems designed for pH, redox, and hypoxia-triggered drug release, showing how polypeptide carriers can concentrate payloads in tumor microenvironments while reducing systemic exposure. Wang and colleagues, in a 2021 review in Biomaterials, reviewed polypeptide-based drug delivery systems for programmed release, emphasizing the biodegradability and low immunogenicity advantages that polypeptide carriers offer over synthetic polymer alternatives. Jao and colleagues, writing in Materials in 2017, reviewed protein-based drug delivery materials, including polypeptide scaffolds used as biocompatible carriers across oncology, gene therapy, and anti-inflammatory applications. As of April 2026, stimuli-responsive polypeptide delivery nanoparticles remain primarily at the preclinical and early-clinical stage; they are not yet a standard clinical delivery platform for FDA-approved therapeutics.

Why This Matters for Your Health

The breadth of polypeptide biology means that polypeptide activity is already central to standard clinical biomarker panels. Fasting insulin directly reflects the activity of the most important endogenous polypeptide hormone. Hemoglobin A1c is the primary outcome measure for GLP-1 and GIP class therapeutics in every major metabolic trial. IGF-1 reflects growth hormone axis activity — the downstream product of the most studied pituitary polypeptide. High-sensitivity CRP reflects the inflammatory state that polypeptide-based antimicrobial and anti-inflammatory biology regulates. Understanding these markers gives the biology its interpretive context.

That principle of measuring first is central to Superpower's approach to preventive health: polypeptide science is not abstract — it is the molecular substrate of the numbers on a standard blood panel, and understanding the biology makes those numbers meaningful rather than arbitrary.

Which Biomarkers Are Relevant if You Are Exploring Polypeptide Biology?

The polypeptide molecules that govern metabolism, growth, appetite, and immune function are measurable through standard bloodwork. Understanding what each marker reflects about underlying polypeptide biology transforms lab results from numbers into a legible biological picture.

• Fasting insulin: Directly measures the activity of insulin, the most clinically important endogenous polypeptide hormone. Elevated fasting insulin is among the earliest detectable markers of insulin resistance, occurring years before glucose dysregulation appears.
• Hemoglobin A1c (HbA1c): The primary endpoint in every GLP-1 and GIP receptor agonist clinical trial. A baseline HbA1c characterizes how the incretin polypeptide system is functioning before any metabolic intervention.
• IGF-1: The principal downstream marker of growth hormone polypeptide activity. IGF-1 levels reflect integrated GH secretion over days and are the standard clinical measure for assessing the GH axis.
• Fasting glucose: A foundational metabolic baseline. Polypeptide hormones including insulin, glucagon, GLP-1, and GIP all regulate postprandial and fasting glucose — making this the most direct measure of how the collective incretin system is performing.
• hs-CRP: Systemic inflammatory marker relevant for evaluating antimicrobial polypeptide biology. Elevated high-sensitivity CRP reflects inflammatory burden that polypeptide-driven immune responses are responding to.
• Triglycerides: Relevant to GLP-1 and GIP class therapies, which produce meaningful triglyceride reductions in phase 3 trials. A baseline triglyceride reading establishes the pre-intervention lipid context.
• Thyroid-stimulating hormone (TSH): Reflects the activity of thyrotropin-releasing hormone (TRH), a tripeptide produced in the hypothalamus that governs the hypothalamic-pituitary-thyroid axis. Baseline TSH is standard in any comprehensive metabolic assessment.

The metabolic health biomarker framework at Superpower's metabolic testing guide covers these markers in the context of insulin resistance and incretin biology, providing the interpretive structure that makes polypeptide-related lab data actionable.

Disclaimer: This page is provided by Superpower Health for educational and informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider.